Peptide 17 alleviates early hypertensive renal injury by regulating the Hippo/YAP signalling pathway

Nephrology - Tập 27 Số 8 - Trang 712-723 - 2022
San‐Bin Xu1, Bin Xu2, Zhi‐Heng Ma1, Mei‐Qin Huang1, Z.Q. GAO3, Jian‐Li Ni1
1Internal Medicine of Traditional Chinese Medicine Xinhua Hospital Chongming Branch Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
2Department of Pharmacy Xinhua Hospital Chongming Branch Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
3Department of Traditional Chinese Medicine Shanghai North Railway Station Hospital Shanghai China

Tóm tắt

AbstractAimHypertensive nephropathy is embodied by kidney tissue fibrosis and glomerular sclerosis, as well as renal inflammation. The Hippo/YAP (yes‐associated protein, YAP) axis has been reported to promote inflammation and fibrosis and may participate in the pathogenesis of heart, vascular and renal injuries. However, the role of the Hippo/YAP pathway in hypertensive renal injury has not been reported so far. We explored the role of the Hippo/YAP signalling pathway in hypertensive renal injury and the effect of peptide 17 on its effects.MethodsHistopathological analyses were performed based on the Masson and Haematoxylin/eosin (HE) staining approaches. Biochemical indexes were determined and immunofluorescence and western blotting were used to detect protein expression levels. The mRNA expression levels were determined by qRT‐PCR.ResultsOur results showed that peptide 17 reduced the systolic blood pressure (SBP) and urine protein/creatinine ratio in hypertensive rats. In addition, peptide 17 reduced the histopathological damage of kidneys in spontaneously hypertensive rats (SHRs). Moreover, peptide 17 downregulated genes in the Hippo/Yap pathway in kidney tissue of SHRs and Ang II‐treated kidney cells. The expression levels of inflammatory factors TNF‐α, IL‐1β and MCP‐1 and the pro‐fibrotic factors TGF‐β1, fibronectin, and CTGF were increased in the kidney of hypertensive rats, but reversed by peptide 17 treatment. Silencing of YAP had effect similar to that of peptide 17 in vivo and in vitro.ConclusionPeptide 17 alleviates early renal injury in hypertension by regulating the Hippo/YAP signalling pathway. These findings may be useful in the treatment of hypertensive renal injury.

Từ khóa


Tài liệu tham khảo

10.1038/s41581-019-0248-y

10.1007/5584_2016_84

10.1159/000343453

10.1038/nrneph.2010.154

10.1002/cphy.c110058

10.1093/ndt/gfu366

10.1681/ASN.2005121256

10.1097/HJH.0000000000001599

Morice S, 2020, The YAP/TEAD Axis as a new therapeutic target in osteosarcoma: effect of Verteporfin and CA3 on primary tumor growth, Cancer, 12

10.3390/cancers11101596

10.1101/gad.1664408

10.1016/j.ceb.2008.10.001

10.1016/j.gene.2016.07.028

10.1016/j.cell.2007.07.019

10.1016/j.cub.2008.02.006

10.1016/j.molcel.2016.10.034

10.1016/j.bbrc.2017.09.105

10.18632/oncotarget.16209

Wei X, 2019, Targeting YAP suppresses ovarian cancer progression through regulation of the PI3K/Akt/mTOR pathway, Oncol Rep, 42, 2768

Fu XY, 2020, TM4SF1 facilitates non‐small cell lung cancer progression through regulating YAP‐TEAD pathway, Eur Rev Med Pharmacol Sci, 24, 1829

10.3390/nu8030165

10.1016/j.jacc.2018.02.073

10.1016/j.tibs.2017.09.003

10.15252/embr.201438638

10.1158/1541-7786.MCR-15-0305

10.1101/gad.219402.113

10.1101/gad.173435.111

10.1073/pnas.1613121113

10.1073/pnas.1524523113

10.1111/bph.13806

Zhou J, 2014, An emerging role for Hippo‐YAP signaling in cardiovascular development, J Biomed Res, 28, 251, 10.7555/JBR.28.20140020

10.1038/nature20602

10.1016/j.trsl.2016.05.003

10.3390/cells5020017

10.1046/j.1523-1755.1999.00721.x

10.1038/ki.2008.516

Möhring J, 1975, Pathogenesis of malignant hypertension: experimental evidence from the renal hypertensive rat, Clin Nephrol, 4, 167

10.1101/gad.888601

Thông tin
Thông tin xuất bản

Nephrology

Tập 27 Số 8

712-723

Thông tin tác giả